

Curriculum Vitae for Finn Sellebjerg

1. Personal data

- Born 8-12 1964
- Work address: Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark
- Home address: Slettevej 22, 2870 Dyssegård, Denmark
- Phone: +45 3545 2286; Fax: +45 3545 2626; E-mail: finn.thorup.sellebjerg@regionh.dk

2. Education

- MD January 29th 1993, University of Copenhagen
- PhD January 30th 1998, University of Copenhagen
- DMSc March 2nd 2004, University of Copenhagen
- National Board of Health of Denmark certified specialist in neurology July 1st 2005

3. Recent positions

- 2006-2013: Associate research professor (5-year position) and associate professor, University of Copenhagen
- 2007-present: Consultant neurologist, Rigshospitalet, University of Copenhagen
- 2013-present: Clinical professor of neurology, University of Copenhagen

4. Academic awards and honours

- The Serono Nordic prize for MS research in 1998
- The Danish Neurological Society poster prize (1st prize) in 2002
- The RoseLiv prize for MS research in 2006
- The Videnskab.dk price for best Danish scientific result in 2011 (with Annette Oturai, Helle Bach Søndergaard and Per Soelberg Sørensen)

5. Scientific focus areas

- Neuroimmunology research in multiple sclerosis and neuroinflammatory disorders
- Cerebrospinal fluid immunology
- Mesenchymal stem cell therapy
- Biomarker research
- Novel clinical trial designs in progressive multiple sclerosis

6. International relations

- Member of the European Conference for Treatment and research in Multiple Sclerosis Council and member of the teaching course committee
- Section editor, Multiple Sclerosis and Related Disorders
- Scientific collaboration with many international MS research groups over the years
- Ad hoc consultant/advisor for companies engaged in MS therapy development

7. Supervision of students

- Supervised 11 completed ph.d. and one DMSc project and 5 ongoing ph.d. projects

- Supervised 4 post-doc fellows

8. Management experience

- Director, Danish Multiple Sclerosis Center, Rigshospitalet since 2015
- Completed OLAU management course 2010 and CBS Executive Research Management Course 2011-2012

9. Publications

- 184 peer-reviewed publications, 21 other publications
- H-index 40; 7,436 citations (Web of Science accessed January 23rd 2019)
- ORCID iD 0000-0002-1333-9623

Ten selected publications within the latest three years

1. Ratzner R, Iversen P, Börnsen L, Dyrby TB, Romme Christensen J, Ammitzbøll C, Madsen CG, Garde E, Lyksborg M, Andersen B, Hyldstrup L, Sørensen PS, Siebner HR, **Sellebjerg F**. A phase 2A study of monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. *Mult Scler* 2016; 22: 926-934.
2. Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzner R, Nielsen BR, Søndergaard HB, von Essen M, **Sellebjerg F**. Smoking reduces circulating CD26hiCD161hi MAIT cells in healthy individuals and patients with multiple sclerosis. *J Leukoc Biol* 2017; 101: 1211-1220.
3. **Sellebjerg F**, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjermand LE, von Essen M, Ratzner R, Sørensen PS, Romme Christensen J. Defining active progressive multiple sclerosis. *Mult Scler* 2017; 23: 1727-1735.
4. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Liu K, Lucas N, Yu B, Arnold, DL, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Miller A, **Sellebjerg F**, Cadavid D, Mikol D, Steiner D. Natalizumab in secondary progressive multiple sclerosis: primary results from ASCEND, a phase 3, randomized, double-blind, placebo-controlled trial with an open label extension. *Lancet Neurol* 2018; 17: 405-415.
5. Boesen MS, Jensen PEH, Magyari M, Born AP, Uldall PV, Blinkenberg M, **Sellebjerg F**. Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes. *Mult Scler Relat Disord* 2018; 24: 175-184.
6. Romme Christensen J, Komori M, von Essen MR, Ratzner R, Börnsen L, Bielekova B, **Sellebjerg F**. CSF biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation. *Mult Scler* [E-pub ahead of print].
7. **Sellebjerg F**, Royen L, Soelberg Sørensen P, Oturai AB, Jensen PEH. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. *Mult Scler* [E-pub ahead of print].
8. Ammitzbøll C., von Essen MR, Börnsen L, McWilliam O, Ratzner R, Romme Christensen J, Oturai AB, Søndergaard HB, **Sellebjerg F**. GPR15+ T cells are Th17 like, increased in smokers and associated with multiple sclerosis. *J Autoimmun* [E-pub ahead of print].
9. International Multiple Sclerosis Genetics Consortium (**Finn Sellebjerg** author 11 out of 137). Low frequency and rare coding variation contributes to multiple sclerosis risk. *Cell* [E-pub ahead of print].
10. von Essen MR, Ammitzbøll C, Hansen RH, Petersen ER, McWilliam O, Marquart HV, Damm NP, **Sellebjerg F**. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. *Brain* [Accepted].

Ten selected publications since 2015

1. Börnsen L, Romme Christensen J, Ratzner R, Hedegaard C, Søndergaard H, Krakauer M, Hesse D, Nielsen CH, Sørensen PS, **Sellebjerg F**. Endogenous interferon-beta-inducible gene expression and interferon-beta-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis. *PLoS One* 2015; 10: e0118830.
2. Modvig S, Degn M, Roed H, Sørensen TL, Larsson HBW, Langkilde AR, Frederiksen JL, **Sellebjerg F**. Cerebrospinal fluid levels of chitinase-3-like-1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. *Mult Scler* 2015; 21: 1761-1770.
3. Laursen JH, Søndergaard HB, Sørensen PS, **Sellebjerg F**, Oturai A. Association between age at onset of multiple sclerosis and environmental and genetic factors of importance for vitamin D levels. *Neurology* 2016; 86: 88-93.
4. Ratzner R, Iversen P, Börnsen L, Dyrby TB, Romme Christensen J, Ammitzbøll C, Madsen CG, Garde E, Lyksborg M, Andersen B, Hyldstrup L, Sørensen PS, Siebner HR, **Sellebjerg F**. A phase 2A study of monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. *Mult Scler* 2016; 22: 926-934.
5. Ammitzbøll C, Börnsen L, Romme Christensen J, Ratzner R, Nielsen BR, Søndergaard HB, von Essen M, **Sellebjerg F**. Smoking reduces circulating CD26hiCD161hi MAIT cells in healthy individuals and patients with multiple sclerosis. *J Leukoc Biol* 2017; 101: 1211-1220.
6. Nielsen BR, Romme Christensen J, Börnsen L, Ratzner R, von Essen MR, **Sellebjerg F**. Characterization of naïve, memory and effector T cells in progressive multiple sclerosis. *J Neuroimmunol* 2017; 310: 17-25.
7. **Sellebjerg F**, Börnsen L, Ammitzbøll C, Nielsen JE, Vinther-Jensen T, Hjermand LE, von Essen M, Ratzner R, Sørensen PS, Romme Christensen J. Defining active progressive multiple sclerosis. *Mult Scler* 2017; 23: 1727-1735.
8. Ammitzbøll C, Dyrby TB, Lyksborg M, Schreiber K, Ratzner R, Romme Christensen J, Iversen P, Magyari M, Garde E, Sørensen PS, Siebner HR, **Sellebjerg F**. Disability in progressive MS is associated with T2 lesion changes *Mult Scler Relat Disord* 2018; 20: 73-78.
9. Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, **Sellebjerg F**, Søndergaard HB. Smoking affects the interferon-beta treatment response in multiple sclerosis. *Neurology* 2018; 90:e593-e600.
10. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Liu K, Lucas N, Yu B, Arnold, DL, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Miller A, **Sellebjerg F**, Cadavid D, Mikol D, Steiner D. Natalizumab in secondary progressive multiple sclerosis: primary results from ASCEND, a phase 3, randomized, double-blind, placebo-controlled trial with an open label extension *Lancet Neurol* [E-pub ahead of print].